Evidence map›Paper›PMID 32674907›Full record

ArticleVaccine2020

Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.

Yu-Jin Jung, Ki-Hye Kim, Eun-Ju Ko, Youri Lee, Min-Chul Kim, Young-Tae Lee, Cheol-Hyun Kim, Subbiah Jeeva, Bo Ryoung Park, Sang-Moo Kang

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Yu-Jin JungCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Ki-Hye KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Eun-Ju KoCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; College of Veterinary Medicine, Jeju National University, Jeju, Jeju-do, Republic of Korea.
Youri LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Min-Chul KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; CARESIDE Co., Ltd., Seongnam, Gyeonggi-do, Republic of Korea.
Young-Tae LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Cheol-Hyun KimDepartment of Animal Resource Science, Dankook University, Cheonan, Chungnam, Republic of Korea.
Subbiah JeevaCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Bo Ryoung ParkCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Sang-Moo KangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. Electronic address: skang24@gsu.edu.
Georgia State University · USDankook University · KR

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
Universal epitopes-based recombinant influenza vaccinesR21AI147042 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2020 to 2021
$428k
Multi NA-based influenza vaccinesR41AI152800 · NIAID · ADVAC, LLC · PI KANG, SANG-MOO · 2020 to 2020
$272k
New RSV Vaccines with Improved Safety and EfficacyR41AI134132 · NIAID · ADVAC, LLC · PI KANG, SANG-MOO · 2018 to 2018
$225k
NIAID NIH HHS R01 AI093772NIAID NIH HHS R21 AI147042NIAID NIH HHS R41 AI134132NIAID NIH HHS R41 AI152800
6 · The paper itself

Abstract

Lactic acid bacteria Lactobacillus casei DK128 isolated from fermented vegetable foods was suggested to stimulate innate immune responses. Here, we investigated whether heat-killed DK128 would exhibit adjuvant effects on enhancing the efficacy of influenza vaccination. Immunization of mice with split influenza virus vaccine in the presence of heat-killed DK128 induced significantly higher levels of both IgG1 and IgG2c isotype antibodies than those by vaccine only. A single dose DK128-adjuvanted influenza vaccination conferred higher efficacy of protection, as evidenced by intact lung function, less weight loss, enhanced clearance of lung viral loads, and lower levels of inflammatory cytokines and infiltrates. Immunization of CD4 T cell-knockout (CD4KO) mice with influenza vaccine and DK128, but not with vaccine alone, induced isotype-switched IgG antibodies and protection against lethal challenge in CD4KO mice. The results in this study suggest heat-killed DK128 as a potential vaccine adjuvant, promoting the induction of IgG isotype switching in CD4-deficient condition and enhancing protective efficacy of split influenza vaccination in immunocompromised and immune-competent subjects.

Indexed as

Influenza, HumanInfluenza VaccinesLacticaseibacillus caseiOrthomyxoviridae InfectionsAdjuvants, ImmunologicAnimalsAntibodies, ViralImmunityMiceMice, Inbred BALB CMice, Inbred C57BLVaccinationAdjuvants, ImmunologicAntibodies, ViralInfluenza VaccinesAdjuvantInfluenza vaccineLactic acid bacteria

Identifiers

PMID32674907
PMCPMC7453881
OpenAlexW3043518538

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.